Phagocytosed Clofazimine Biocrystals Can Modulate Innate Immune Signaling by Inhibiting TNFα and Boosting IL-1RA Secretion

Molecular Pharmaceutics

Volumn 12, Issue 7, 2015, Pages 2517-2527

  Yoon, Gi S ^a   Sud, Sudha ^a   Keswani, Rahul K ^a   Baik, Jason ^a,c   Standiford, Theodore J ^b   Stringer, Kathleen A ^a   Rosania, Gus R ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c Optivia Biotechnology Inc   (United States)

Author keywords

biocompatibility; cell signaling; drug delivery; immunomodulation; liquid crystal; macrophage

Indexed keywords

CASPASE 3; CLOFAZIMINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; PROTEIN KINASE B; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; ANTIINFLAMMATORY AGENT; IL1RN PROTEIN, MOUSE; TUMOR NECROSIS FACTOR;

ANIMAL CELL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; BIOCHEMISTRY; BIOCOMPATIBILITY; COMPARATIVE STUDY; CONTROLLED STUDY; CRYSTAL LIKE DRUG INCLUSION; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOTOXICITY; DETOXIFICATION; DRUG ACCUMULATION; DRUG SOLUBILITY; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; INNATE IMMUNITY; LIQUID CRYSTAL; LUNG ALVEOLUS MACROPHAGE; MACROPHAGE; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CELL LINE; DRUG EFFECTS; IMMUNOLOGY; METABOLISM; MITOCHONDRION; SIGNAL TRANSDUCTION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; APOPTOSIS; CELL LINE; CLOFAZIMINE; IMMUNITY, INNATE; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; MACROPHAGES; MICE; MICE, INBRED C57BL; MITOCHONDRIA; NF-KAPPA B; PHAGOCYTOSIS; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84936757652     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/acs.molpharmaceut.5b00035     Document Type: Article

References (68)

1. Barry, V. C.; Belton, J. G.; Conalty, M. L.; Denney, J. M.; Edward, D. W.; O'Sullivan, J. F.; Twomey, D.; Winder, F. A New Series of Phenazines (rimino-Compounds) with High Antituberculosis Activity Nature 1957, 179, 1013-1015
2. Cholo, M. C.; Steel, H. C.; Fourie, P. B.; Germishuizen, W. A.; Anderson, R. Clofazimine: Current Status and Future Prospects J. Antimicrob. Chemother. 2012, 67, 290-298
3. Atkinson, A. J.; Sheagren, J. N.; Rubio, J. B.; Knight, V. Evaluation of B.663 in Human Leprosy. Int. J. Lepr. Other Mycobact. Dis. 35, 119-127.
4. Mansfield, R. E. Tissue Concentrations of Clofazimine (B663) in Man Am. J. Trop. Med. Hyg. 1974, 23, 1116-1119
5. Baik, J.; Rosania, G. R. Macrophages Sequester Clofazimine in an Intracellular Liquid Crystal-like Supramolecular Organization PLoS One 2012, 7, e47494
6. Baik, J.; Rosania, G. R. Molecular Imaging of Intracellular Drug-Membrane Aggregate Formation Mol. Pharmaceutics 2011, 8, 1742-1749
7. Schaad-Lanyi, Z.; Dieterle, W.; Dubois, J. P.; Theobald, W.; Vischer, W. Pharmacokinetics of Clofazimine in Healthy Volunteers Int. J. Lepr. Other Mycobact. Dis. 1987, 55, 9-15
8. Lu, Y.; Zheng, M.; Wang, B.; Fu, L.; Zhao, W.; Li, P.; Xu, J.; Zhu, H.; Jin, H.; Yin, D.; Huang, H.; Upton, A. M.; Ma, Z. Clofazimine Analogs with Efficacy against Experimental Tuberculosis and Reduced Potential for Accumulation Antimicrob. Agents Chemother. 2011, 55, 5185-5193
9. Baik, J.; Stringer, K. a; Mane, G.; Rosania, G. R. Multiscale Distribution and Bioaccumulation Analysis of Clofazimine Reveals a Massive Immune System-Mediated Xenobiotic Sequestration Response Antimicrob. Agents Chemother. 2013, 57, 1218-1230
10. Levy, L. Pharmacologic Studies of Clofazimine Am. J. Trop. Med. Hyg. 1974, 23, 1097-1109
11. Holdiness, M. R. Clinical Pharmacokinetics of Clofazimine. A Review Clin. Pharmacokinet. 1989, 16, 74-85
12. Harbeck, R. J.; Worthen, G. S.; Lebo, T. D.; Peloquin, C. A. Clofazimine Crystals in the Cytoplasm of Pulmonary Macrophages Ann. Pharmacother. 1999, 33, 250
13. Lewis, J. T.; Candelora, J. N.; Hogan, R. B.; Briggs, F. R.; Abraham, S. C. Crystal-Storing Histiocytosis due to Massive Accumulation of Charcot-Leyden Crystals: A Unique Association Producing Colonic Polyposis in a 78-Year-Old Woman with Eosinophilic Colitis Am. J. Surg. Pathol. 2007, 31, 481-485
14. Jadhav, M. V.; Sathe, A. G.; Deore, S. S.; Patil, P. G.; Joshi, N. G.; Joghi, N. G. Tissue Concentration, Systemic Distribution and Toxicity of Clofazimine - an Autopsy Study Indian J. Pathol. Microbiol. 2004, 47, 281-283
15. Desikan, K. V.; Ramanujam, K.; Ramu, G.; Balakrishnan, S. Autopsy Findings in a Case of Lepromatous Leprosy Treated with Clofazimine Lepr. Rev. 1975, 46, 181-189
16. Lo, J. S.; Berg, R. E.; Tomecki, K. J. Treatment of Discoid Lupus Erythematosus Int. J. Dermatol. 1989, 28, 497-507
17. Mackey, J. P.; Barnes, J. Clofazimine in the Treatment of Discoid Lupus Erythematosus Br. J. Dermatol. 1974, 91, 93-96
18. Chuaprapaisilp, T.; Piamphongsant, T. Treatment of Pustular Psoriasis with Clofazimine Br. J. Dermatol. 1978, 99, 303-305
19. Podmore, P.; Burrows, D. Clofazimine - an Effective Treatment for Melkersson-Rosenthal Syndrome or Miescher's Cheilitis Clin. Exp. Dermatol. 1986, 11, 173-178
20. Arbiser, J. L.; Moschella, S. L. Clofazimine: A Review of Its Medical Uses and Mechanisms of Action J. Am. Acad. Dermatol. 1995, 32, 241-247
21. Medeiros Bezerra, E. L.; Pereira Vilar, M. J.; Da Trindade Neto, P. B.; Sato, E. I. Double-Blind, Randomized, Controlled Clinical Trial of Clofazimine Compared with Chloroquine in Patients with Systemic Lupus Erythematosus Arthritis Rheum. 2005, 52, 3073-3078
22. Venkateswarlu, B.; Venkataramana, D.; Rao, A. V.; Prabhakar, M. C.; Reddy, B. M. Role of Rifampin and Clofazimine Ointments in the Treatment of Leprosy Int. J. Lepr. Other Mycobact. Dis. 1992, 60, 269-270
23. Keswani, R. K.; Baik, J.; Yeomans, L.; Hitzman, C.; Johnson, A.; Pawate, A.; Kenis, P. J.; Rodriguez-Hornedo, N.; Stringer, K. A.; Rosania, G. R. Chemical Analysis of Drug Biocrystals: A Role for Counterion Transport Pathways in Intracellular Drug Disposition Mol. Pharmaceutics 2015, 10.1021/acs.molpharmaceut.5b00032
24. Fukutomi, Y.; Maeda, Y.; Makino, M. Apoptosis-Inducing Activity of Clofazimine in Macrophages Antimicrob. Agents Chemother. 2011, 55, 4000-4005
25. Savill, J. Apoptosis in Resolution of Inflammation J. Leukoc. Biol. 1997, 61, 375-380
26. Marriott, H. M.; Hellewell, P. G.; Cross, S. S.; Ince, P. G.; Whyte, M. K. B.; Dockrell, D. H. Decreased Alveolar Macrophage Apoptosis Is Associated with Increased Pulmonary Inflammation in a Murine Model of Pneumococcal Pneumonia J. Immunol. 2006, 177, 6480-6488
27. Henson, P. M.; Bratton, D. L. Antiinflammatory Effects of Apoptotic Cells J. Clin. Invest. 2013, 123, 2773-2774
28. Troutman, T. D.; Bazan, J. F.; Pasare, C. Toll-like Receptors, Signaling Adapters and Regulation of the pro-Inflammatory Response by PI3K Cell Cycle 2012, 11, 3559-3567
29. Drexler, S. K.; Foxwell, B. M. The Role of Toll-like Receptors in Chronic Inflammation Int. J. Biochem. Cell Biol. 2010, 42, 506-518
30. Takeuchi, O.; Akira, S. Pattern Recognition Receptors and Inflammation Cell 2010, 140, 805-820
31. Kawai, T.; Akira, S. The Role of Pattern-Recognition Receptors in Innate Immunity: Update on Toll-like Receptors Nat. Immunol. 2010, 11, 373-384
32. Mehta, S. B.; Shribak, M.; Oldenbourg, R. Polarized Light Imaging of Birefringence and Diattenuation at High Resolution and High Sensitivity. J. Opt. 2013, 15.
33. Fuseler, J. W.; Merrill, D. M.; Rogers, J. A.; Grisham, M. B.; Wolf, R. E. Analysis and Quantitation of NF-kappaB Nuclear Translocation in Tumor Necrosis Factor Alpha (TNF-Alpha) Activated Vascular Endothelial Cells Microsc. Microanal. 2006, 12, 269-276
34. Noursadeghi, M.; Tsang, J.; Haustein, T.; Miller, R. F.; Chain, B. M.; Katz, D. R. Quantitative Imaging Assay for NF-kappaB Nuclear Translocation in Primary Human Macrophages J. Immunol. Methods 2008, 329, 194-200
35. Min, K. A.; Rajeswaran, W. G.; Oldenbourg, R.; Harris, G.; Keswani, R. K.; Chiang, M.; Talattof, A.; Hafeez, M.; Horobin, R. W.; Larsen, S. D.; Stringer, K. A.; Rosania, G. R. Massive Bioaccumulation and Self-Assembly of Phenazine Compounds in Live Cells Adv. Sci. 2015, 10.1002/advs.201500025
36. Magenau, A.; Benzing, C.; Proschogo, N.; Don, A. S.; Hejazi, L.; Karunakaran, D.; Jessup, W.; Gaus, K. Phagocytosis of IgG-Coated Polystyrene Beads by Macrophages Induces and Requires High Membrane Order Traffic 2011, 12, 1730-1743
37. Molnarfi, N.; Gruaz, L.; Dayer, J.-M.; Burger, D. Opposite Regulation of IL-1 and Secreted IL-1 Receptor Antagonist Production by Phosphatidylinositide-3 Kinases in Human Monocytes Activated by Lipopolysaccharides or Contact with T Cells J. Immunol. 2006, 178, 446-454
38. Rehani, K.; Wang, H.; Garcia, C. A.; Kinane, D. F.; Martin, M. Toll-like Receptor-Mediated Production of IL-1Ra Is Negatively Regulated by GSK3 via the MAPK ERK1/2 J. Immunol. 2009, 182, 547-553
39. Morris, M. C.; Gilliam, E. A.; Li, L. Innate Immune Programing by Endotoxin and Its Pathological Consequences. Front. Immunol. 2015, 5.
40. Cheng, A. M.; Handa, P.; Tateya, S.; Schwartz, J.; Tang, C.; Mitra, P.; Oram, J. F.; Chait, A.; Kim, F. Apolipoprotein A-I Attenuates Palmitate-Mediated NF-κB Activation by Reducing Toll-like Receptor-4 Recruitment into Lipid Rafts PLoS One 2012, 7, e33917
41. Kim, K.; Jung, N.; Lee, K.; Choi, J.; Kim, S.; Jun, J.; Kim, E.; Kim, D. Dietary Omega-3 Polyunsaturated Fatty Acids Attenuate Hepatic Ischemia/reperfusion Injury in Rats by Modulating Toll-like Receptor Recruitment into Lipid Rafts Clin. Nutr. 2013, 32, 855-862
42. Wong, S. W.; Kwon, M.-J.; Choi, A. M. K.; Kim, H.-P.; Nakahira, K.; Hwang, D. H. Fatty Acids Modulate Toll-like Receptor 4 Activation through Regulation of Receptor Dimerization and Recruitment into Lipid Rafts in a Reactive Oxygen Species-Dependent Manner J. Biol. Chem. 2009, 284, 27384-27392
43. Lee, C. C.; Avalos, A. M.; Ploegh, H. L. Accessory Molecules for Toll-like Receptors and Their Function Nat. Rev. Immunol. 2012, 12, 168-179
44. Carpintero, R.; Brandt, K. J.; Gruaz, L.; Molnarfi, N.; Lalive, P. H.; Burger, D. Glatiramer Acetate Triggers PI3Kδ/Akt and MEK/ERK Pathways to Induce IL-1 Receptor Antagonist in Human Monocytes Proc. Natl. Acad. Sci. U.S.A. 2010, 107, 17692-17697
45. Dinarello, C. A.; Simon, A.; van der Meer, J. W. M. Treating Inflammation by Blocking Interleukin-1 in a Broad Spectrum of Diseases Nat. Rev. Drug Discovery 2012, 11, 633-652
46. Shi, Y.; Mucsi, A. D.; Ng, G. Monosodium Urate Crystals in Inflammation and Immunity Immunol. Rev. 2010, 233, 203-217
47. Grebe, A.; Latz, E. Cholesterol Crystals and Inflammation Curr. Rheumatol. Rep. 2013, 15, 313
48. Magro, F.; Portela, F. Management of Inflammatory Bowel Disease with Infliximab and Other Anti-Tumor Necrosis Factor Alpha Therapies BioDrugs 2010, 24 (Suppl 1) 3-14
49. Maini, R.; St Clair, E. W.; Breedveld, F.; Furst, D.; Kalden, J.; Weisman, M.; Smolen, J.; Emery, P.; Harriman, G.; Feldmann, M.; Lipsky, P. Infliximab (chimeric Anti-Tumour Necrosis Factor Alpha Monoclonal Antibody) versus Placebo in Rheumatoid Arthritis Patients Receiving Concomitant Methotrexate: A Randomised Phase III Trial. ATTRACT Study Group Lancet 1999, 354, 1932-1939
50. Lethaby, A.; Lopez-Olivo, M. A.; Maxwell, L.; Burls, A.; Tugwell, P.; Wells, G. A. Etanercept for the Treatment of Rheumatoid Arthritis Cochrane Database Syst. Rev. 2013, 5, CD004525
51. Gall, J. S.; Kalb, R. E. Infliximab for the Treatment of Plaque Psoriasis Biologics 2008, 2, 115-124
52. Kivelevitch, D.; Mansouri, B.; Menter, A. Long Term Efficacy and Safety of Etanercept in the Treatment of Psoriasis and Psoriatic Arthritis Biologics 2014, 8, 169-182
53. Hernandez, M. L.; Mills, K.; Almond, M.; Todoric, K.; Aleman, M. M.; Zhang, H.; Zhou, H.; Peden, D. B. IL-1 Receptor Antagonist Reduces Endotoxin-Induced Airway Inflammation in Healthy Volunteers J. Allergy Clin. Immunol. 2015, 135, 379-385
54. Meyer, N. J.; Feng, R.; Li, M.; Zhao, Y.; Sheu, C.-C.; Tejera, P.; Gallop, R.; Bellamy, S.; Rushefski, M.; Lanken, P. N.; Aplenc, R.; O'Keefe, G. E.; Wurfel, M. M.; Christiani, D. C.; Christie, J. D. IL1RN Coding Variant Is Associated with Lower Risk of Acute Respiratory Distress Syndrome and Increased Plasma IL-1 Receptor Antagonist Am. J. Respir. Crit. Care Med. 2013, 187, 950-959
55. Grailer, J. J.; Canning, B. A.; Kalbitz, M.; Haggadone, M. D.; Dhond, R. M.; Andjelkovic, A. V.; Zetoune, F. S.; Ward, P. A. Critical Role for the NLRP3 Inflammasome during Acute Lung Injury J. Immunol. 2014, 192, 5974-5983
56. Hudock, K. M.; Liu, Y.; Mei, J.; Marino, R. C.; Hale, J. E.; Dai, N.; Worthen, G. S. Delayed Resolution of Lung Inflammation in Il-1rn-/- Mice Reflects Elevated IL-17A/granulocyte Colony-Stimulating Factor Expression Am. J. Respir. Cell Mol. Biol. 2012, 47, 436-444
57. Ischenko, A. M.; Nikolaev, B. P.; Kotova, T. V.; Vorobeychikov, E. V.; Konusova, V. G.; Yakovleva, L. Y. IL-1 Receptor Antagonist as an Aerosol in Inflammation J. Aerosol Med. 2007, 20, 445-459
58. Ritter, M.; Straubinger, K.; Schmidt, S.; Busch, D. H.; Hagner, S.; Garn, H.; Prazeres da Costa, C.; Layland, L. E. Functional Relevance of NLRP3 Inflammasome-Mediated Interleukin (IL)-1β during Acute Allergic Airway Inflammation Clin. Exp. Immunol. 2014, 178, 212-223
59. Nold, M. F.; Mangan, N. E.; Rudloff, I.; Cho, S. X.; Shariatian, N.; Samarasinghe, T. D.; Skuza, E. M.; Pedersen, J.; Veldman, A.; Berger, P. J.; Nold-Petry, C. A. Interleukin-1 Receptor Antagonist Prevents Murine Bronchopulmonary Dysplasia Induced by Perinatal Inflammation and Hyperoxia Proc. Natl. Acad. Sci. U.S.A. 2013, 110, 14384-14389
60. Basu, J.; Shin, D.-M.; Jo, E.-K. Mycobacterial Signaling through Toll-like Receptors Front. Cell. Infect. Microbiol. 2012, 2, 145
61. Kleinnijenhuis, J.; Oosting, M.; Joosten, L. a B.; Netea, M. G.; Van Crevel, R. Innate Immune Recognition of Mycobacterium Tuberculosis Clin. Dev. Immunol. 2011, 2011, 405310
62. Walker, S. L.; Roberts, C. H.; Atkinson, S. E.; Khadge, S.; Macdonald, M.; Neupane, K. D.; Ranjit, C.; Sapkota, B. R.; Dhakal, S.; Hawksworth, R. A.; Mahat, K.; Ruchal, S.; Hamal, S.; Hagge, D. A.; Lockwood, D. N. J. The Effect of Systemic Corticosteroid Therapy on the Expression of Toll-like Receptor 2 and Toll-like Receptor 4 in the Cutaneous Lesions of Leprosy Type 1 Reactions Br. J. Dermatol. 2012, 167, 29-35
63. Chang, Z. L. Important Aspects of Toll-like Receptors, Ligands and Their Signaling Pathways Inflamm. Res. 2010, 59, 791-808
64. Yoon, G. S.; Dong, C.; Gao, N.; Kumar, A.; Standiford, T. J.; Yu, F.-S. X. Interferon Regulatory Factor-1 in Flagellin-Induced Reprogramming: Potential Protective Role of CXCL10 in Cornea Innate Defense against Pseudomonas Aeruginosa Infection Invest. Ophthalmol. Vis. Sci. 2013, 54, 7510-7521
65. Kovach, M. A.; Standiford, T. J. Toll like Receptors in Diseases of the Lung Int. Immunopharmacol. 2011, 11, 1399-1406
66. Qian, C.; Cao, X. Regulation of Toll-like Receptor Signaling Pathways in Innate Immune Responses Ann. N.Y. Acad. Sci. 2013, 1283, 67-74
67. Kondo, T.; Kawai, T.; Akira, S. Dissecting Negative Regulation of Toll-like Receptor Signaling Trends Immunol. 2012, 33, 449-458
68. Hennessy, E. J.; Parker, A. E.; O'Neill, L. A. J. Targeting Toll-like Receptors: Emerging Therapeutics? Nat. Rev. Drug Discovery 2010, 9, 293-307